SAN FRANCISCO ­– Data from Bristol-Myers Squibb Co. and Merck & Co. Inc. reported at the 56th Annual American Society of Hematology suggest that their PD-1 immunotherapies, Opdivo (nivolumab) and Keytruda (pembrolizumab) respectively, may prove to be powerful tools against lymphomas.